Tty Biopharm
Tty Biopharm Corporation, commonly referred to as Tty Biopharm, is a prominent player in the biopharmaceutical industry, headquartered in Taiwan (TW). Founded in 1966, the company has established itself as a leader in the development and manufacturing of innovative pharmaceuticals, particularly in oncology and other therapeutic areas. With a strong presence in both domestic and international markets, Tty Biopharm is renowned for its commitment to quality and research-driven solutions. The company’s core offerings include a diverse range of generic and proprietary medications, distinguished by their efficacy and safety profiles. Notable achievements include strategic partnerships and a robust pipeline of products that cater to unmet medical needs, solidifying Tty Biopharm's position as a trusted name in the biopharmaceutical landscape.
DitchCarbon Score
How does Tty Biopharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Furniture Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tty Biopharm's score of 30 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Tty Biopharm's reported carbon emissions
In 2023, Tty Biopharm reported total carbon emissions of approximately 9,484,000 kg CO2e. This figure includes 1,700,220 kg CO2e from Scope 1 emissions, 8,488,800 kg CO2e from Scope 2 emissions, and 2,549,520 kg CO2e from Scope 3 emissions. Notably, the Scope 3 emissions include 2,001,170 kg CO2e attributed to purchased goods and services. Over the years, Tty Biopharm has shown fluctuations in its emissions. For instance, in 2022, the total emissions were about 8,836,000 kg CO2e, with Scope 1 at 1,535,320 kg CO2e, Scope 2 at 8,232,490 kg CO2e, and Scope 3 at 3,041,940 kg CO2e. The company has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or any formal climate pledges. The emissions data indicates a need for Tty Biopharm to enhance its climate commitments, particularly in reducing Scope 3 emissions, which represent a significant portion of its total carbon footprint. As the company continues to operate in a climate-conscious industry, establishing clear reduction targets could bolster its sustainability efforts and align with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 1,219,000 | 000,000 | 0,000,000 | 000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 6,845,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 8,065,000 | 0,000,000 | 0,000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Tty Biopharm is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
